Provectus Biopharmaceuticals Inc.

351 articles about Provectus Biopharmaceuticals Inc.

• Provectus Announces Two Poster Presentations On PV-10 For Liver Tumors

  12/22/2016

• Provectus Announces Agreement With POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium) To Study Potential Of PV-10 For Pediatric Cancer

  12/8/2016

• Provectus Announces Notification Of NYSE MKT Listing Deficiency

  12/1/2016

• Provectus Announces Poster Presentation On PV-10 At Society For Immunotherapy Of Cancer 2016 Annual Meeting

  11/14/2016

• Provectus Reports Third Quarter 2016 Financial Results

  11/11/2016

• Provectus Will Hold Its 2016 Third Quarter Business Update Conference Call On Monday, November 14, 2016, At 4 PM Eastern Standard Time

  10/25/2016

• Trading In Provectus Common Stock And Warrants Suspended By NYSE MKT

  10/17/2016

• Provectus Announces Poster Presentation On PV-10 At European Society Of Medical Oncology 2016 Congress Now Available Online

  10/11/2016

• Provectus Announces Poster Presentation On PV-10 At European Society Of Medical Oncology 2016 Congress Now Available Online

  10/11/2016

• Provectus Files Registration Statement For Rights Offering To Existing Stockholders

  10/6/2016

• Provectus Announces Acceptance Of Abstract For Poster Presentation At 31st SITC Annual Meeting

  9/27/2016

• Provectus To Present At Rodman & Renshaw's 18th Annual Global Investment Conference

  9/8/2016

• Provectus Announces Closing Of Public Offering

  8/31/2016

• Provectus Announces Proposed Public Offering Of Preferred Stock And Warrants

  8/25/2016

• Provectus Announces Pricing Of Public Offering To Raise $6 Million

  8/25/2016

• Provectus Receives Patent From USPTO Related To Rose Bengal Analogs

  8/23/2016

• ProvectusReports Second Quarter 2016 Financial Results

  8/10/2016

• Provectus Announces Poster Presentation On PV-10 For Melanoma At European Society For Medical Oncology 2016 Congress

  8/1/2016

• Provectus Will Hold Its 2016 Second Quarter Business Update Conference Call On Wednesday, August 10, 2016, At 4 PM Eastern Daylight Time

  7/20/2016

• Provectus Receives Patent Allowance For Use Of Halogenated Xanthenes In Pharmaceutical Compositions And As Medicaments

  7/18/2016